Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: A nurse's perspective

Supportive Care in Cancer

Volumn 20, Issue 8, 2012, Pages 1601-1611

  Rubin, Krista M ^a   Vona, Karen ^b   Madden, Kathleen ^c   McGettigan, Suzanne ^d   Braun, Ilana M ^e  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; Adverse effects; Interferon alfa; Therapy management

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE; DEXAMETHASONE; FIBRIC ACID DERIVATIVE; GRANISETRON; HYDROMORPHONE; LOPERAMIDE; LORAZEPAM; METHYLPHENIDATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PARACETAMOL; PEGINTERFERON ALPHA2B; PETHIDINE; PREDNISONE; PROCHLORPERAZINE; PROTON PUMP INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CHILL; COGNITIVE THERAPY; COLITIS; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; FATIGUE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HUMAN; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; MELANOMA; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROCLINICAL TOXICITY; NEUROMOTOR TOXICITY; NEUROPSYCHIATRIC TOXICITY; NEUROTOXICITY; NURSE; OVERALL SURVIVAL; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; RIGOR; SEXUAL DYSFUNCTION; SOCIAL SUPPORT; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TASTE DISORDER; THYROID DISEASE; VOMITING; XEROSIS;

HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MELANOMA; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 84863986611     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1473-0     Document Type: Review

References (58)

1. American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society. http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed 14 Feb 2012
2. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129(7):1666-1674. doi:10.1038/jid.2008.423
3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (2011) SEER cancer statistics review, 1975-2008. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975- 2008/sections.html. Accessed 14 Feb 2012
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199-6206. doi:10.1200/JCO.2009.23.4799
5. Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102(7):493-501. doi:10.1093/jnci/djq009
6. Rubin KM, Lawrence DP (2009) Your patient with melanoma: staging, prognosis, and treatment. Oncology (Williston Park) 23(8 Suppl):13-21
7. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) Highand low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18 (12):2444-2458
8. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIBIII melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19(9):2370-2380
9. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of highrisk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7-17
10. Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dr?no B, Kirkwood JM (2008) Practical guidelines for the management of interferon-?-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112(5):982-994. doi:10.1002/cncr.23251
11. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L (2002) Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20(17):3703-3718
12. Merck&Co. Inc. (2011) Product information. Intron®A interferon alfa-2b, recombinant for injection. http://www.spfiles.com/piintrona.pdf. Accessed 26 Sep 2011
13. Haeuber D(1995) The flu-like syndrome. In: Rieger P (ed) Biotherapy: a comprehensive overview. Jones and Bartlett, Boston, pp 243-258
14. Grant M (1997) Nausea and vomiting, quality of life, and the oncology nurse. Oncol Nurs Forum 24(7):5-7
15. National Comprehensive Cancer Network (2010) NCCN Clinical Practice Guidelines in Oncology™ Antiemesis. http://www.nccn.org/professionals/ physician-gls/pdf/antiemesis.pdf. Accessed 8 Feb 2012
16. Malik UR, Makower DF, Wadler S (2001) Interferon-mediated fatigue. Cancer 92(6 Suppl):1664-1668. doi:10.1002/1097-014 (20010915)92:6+<1664::AID- CNCR1494>3.0.CO;2-9
17. Eckert RM (2001) Understanding anticipatory nausea. Oncol Nurs Forum 28(10):1553-1558
18. Piper BF, Rieger PT, Brophy L, Haeuber D, Hood LE, Lyver A, Sharp E (1989) Recent advances in the management of biotherapyrelated side effects: fatigue. Oncol Nurs Forum 16(6 Suppl):27-34
19. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117-126. doi:10.1016/S0140- 6736(08)61033-8
20. Wells JN, Fedric T (2001) Helping patients manage cancer-related fatigue. Home Healthc Nurse 19(8):486-493
21. Johnson JE, Nail LM, Lauver D, King KB, Keys H (1988) Reducing the negative impact of radiation therapy on functional status. Cancer 61(1):46-51
22. Clark PM, Lacasse C (1998) Cancer-related fatigue: clinical practice issues. Clin J Oncol Nurs 2(2):45-53
23. Kiley KE, Gale DM (1998) Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b. Clin J Oncol Nurs 2(1):11-16
24. Ream E, Richardson A (1999) From theory to practice: designing interventions to reduce fatigue in patients with cancer. Oncol Nurs Forum 26(8):1295-1303
25. Schwartz AL (1998) Patterns of exercise and fatigue in physically active cancer survivors. Oncol Nurs Forum 25(3):485-491
26. Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR (2007) Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12 (Suppl 1):11-21. doi:10.1634/ theoncologist.12-S1-11
27. McCorkle R (1987) The measurement of symptom distress. Semin Oncol Nurs 3(4):248-256
28. Glaus A (1993) Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Support Care Cancer 1(6):305-315
29. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186-1196. doi:10.1002/(SICI)1097- 0142 (19990301)85:53.0.CO;2-N
30. Smets EM, Garssen B, Bonke B, De Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39(3):315-325
31. Piper BF, Dibble SL, Dodd MJ,Weiss MC, Slaughter RE, Paul SM (1998) The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25(4):677-684
32. Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK, Greenberg H, Lyman G (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7(4):301-310
33. Mitchell SA, Beck SL, Hood LE, Moore K, Tanner ER (2007) Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 11(1):99-113. doi:10.1188/07.CJON. 99-113
34. National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology™ for Cancer-Related Fatigue. Version 1.2012. http://www.nccn.org/professionals/physician-gls/pdf/fatigue.pdf. Accessed 8 Feb 2012
35. Schwartz AL, Thompson JA, Masood N (2002) Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 29(7):E85-E90
36. Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, Hauschild A, Goldsmith CH, Schaefer M (2010) Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 51(6):466-473. doi:10.1176/appi.psy.51. 6.466
37. Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH (2009) Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 119(1-3):181-185. doi:10.1016/j.jad.2009.02.017
38. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Washington
39. Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-?: recognition and management. CNS Drugs 19(2):105-123
40. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26(5):643-652. doi:10.1016/S0893-133X(01)00407-9
41. Capuron L, Ravaud A, Miller AH, Dantzer R (2004) Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18(3):205-213. doi:10.1016/j.bbi.2003.11.004
42. Fulcher CD, Badger T, Gunter AK, Marrs JA, Reese JM (2008) Putting evidence into practice: interventions for depression. Clin J Oncol Nurs 12(1):131-140. doi:10.1188/08.CJON.131-140
43. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344(13):961-966. doi:10.1056/ NEJM200103293441303
44. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG (2000) Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 89(2):356-362
45. Hauschild A, Kähler KC, Schäfer M, Fluck M (2008) Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol Ges 6(10):829-837. doi:10.1111/j.1610-0387.2008.06651.x, 829-838
46. Adams F, Fernandez F, Mavligit G (1988) Interferon-induced organic mental disorders associated with unsuspected preexisting neurologic abnormalities. J Neurooncol 6(4):355-359
47. Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34-55
48. Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK (2011) Pharmacokinetic/ pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 67(3):657-666. doi:10.1007/s00280-010-1326- 9
49. Wong SF, Jakowatz JG, Taheri R (2004) Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 38(10):1655-1659. doi:10.1345/aph.1D546aph.1D546
50. Hughes M (1996) Sexuality issues: keeping your cool. Oncol Nurs Forum 23:1597-1600
51. Shell JA (2002) Evidence-based practice for symptom management in adults with cancer: sexual dysfunction. Oncol Nurs Forum 29(1):53-66
52. Britton GR (1999) Selective serotonin reuptake inhibitors: implications for advanced nursing practice. J Am Acad Nurse Pract 11 (9):389-395
53. Lovejoy NC, Tabor D, Deloney P (2000) Cancer-related depression: part II-neurologic alterations and evolving approaches to psychopharmacology. Oncol Nurs Forum 27(5):795-808
54. Ferrell BR, Dow KH, Leigh S, Ly J, Gulasekaram P (1995) Quality of life in long-term cancer survivors. Oncol Nurs Forum 22 (6):915-922
55. Rieger P (ed) (1995) Biotherapy: a comprehensive overview. Jones and Bartlett, Sudbury
56. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (7):709-718. doi:10.1056/NEJMoa053007
57. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, Weissel M (1992) Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90(3):363-367
58. Jones TH, Wadler S, Hupart KH (1998) Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 25(1 Suppl 1):54-63